4-methylumbelliferyl-galactopyranoside and Disease Models, Animal

4-methylumbelliferyl-galactopyranoside has been researched along with Disease Models, Animal in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chiba, Y; Fukushige, T; Itoh, K; Jigami, Y; Kanekura, T; Kawashima, I; Kuroda, M; Ohashi, T; Ohno, K; Sakuraba, H; Sugawara, K; Suzuki, T; Tajima, Y; Togawa, T; Tsukimura, T	1
Hagenbeek, A; Hendrikx, PJ; Martens, AC; Visser, JW	1

Other Studies

2 other study(ies) available for 4-methylumbelliferyl-galactopyranoside and Disease Models, Animal

Article	Year
Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. American journal of human genetics, 2009, Volume: 85, Issue:5 Topics: alpha-N-Acetylgalactosaminidase; Amino Acid Substitution; Animals; Binding Sites; Catalysis; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Culture Media, Conditioned; Disease Models, Animal; DNA, Complementary; Drug Stability; Enzyme Replacement Therapy; Fabry Disease; Fibroblasts; Fluorescent Dyes; Galactosides; Genetic Vectors; Humans; Hydrogen-Ion Concentration; Hymecromone; Immunohistochemistry; Kidney; Liver; Mice; Mice, Knockout; Models, Molecular; Molecular Weight; Myocardium; Recombinant Proteins; Retroviridae; Transfection; Trihexosylceramides	2009
Differential suppression of background mammalian lysosomal beta-galactosidase increases the detection sensitivity of LacZ-marked leukemic cells. Analytical biochemistry, 1994, Nov-01, Volume: 222, Issue:2 Topics: Animals; beta-Galactosidase; Disease Models, Animal; Escherichia coli; Galactose; Galactosides; Genetic Markers; Hydrogen-Ion Concentration; Hymecromone; In Vitro Techniques; Kinetics; Leukemia, Myeloid, Acute; Lysosomes; Rats; Rats, Inbred BN; Sensitivity and Specificity; Substrate Specificity	1994

Article

Year

Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease.

American journal of human genetics, 2009, Volume: 85, Issue:5

Topics: alpha-N-Acetylgalactosaminidase; Amino Acid Substitution; Animals; Binding Sites; Catalysis; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Culture Media, Conditioned; Disease Models, Animal; DNA, Complementary; Drug Stability; Enzyme Replacement Therapy; Fabry Disease; Fibroblasts; Fluorescent Dyes; Galactosides; Genetic Vectors; Humans; Hydrogen-Ion Concentration; Hymecromone; Immunohistochemistry; Kidney; Liver; Mice; Mice, Knockout; Models, Molecular; Molecular Weight; Myocardium; Recombinant Proteins; Retroviridae; Transfection; Trihexosylceramides

2009

Differential suppression of background mammalian lysosomal beta-galactosidase increases the detection sensitivity of LacZ-marked leukemic cells.

Analytical biochemistry, 1994, Nov-01, Volume: 222, Issue:2

Topics: Animals; beta-Galactosidase; Disease Models, Animal; Escherichia coli; Galactose; Galactosides; Genetic Markers; Hydrogen-Ion Concentration; Hymecromone; In Vitro Techniques; Kinetics; Leukemia, Myeloid, Acute; Lysosomes; Rats; Rats, Inbred BN; Sensitivity and Specificity; Substrate Specificity

1994